[Federal Register Volume 67, Number 184 (Monday, September 23, 2002)]
[Notices]
[Pages 59526-59528]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-24034]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as 
amended most recently at 67 FR 42268-71, dated June 21, 2002) is 
amended to restructure the Epidemiology and Surveillance Division, 
National Immunization Program.
    Section C-B, Organization and Functions, if hereby amended as 
follows:
    Delete the functional statement for the Epidemiology and 
Surveillance Division (CJ3), and insert the following:
    (1) Directs all Program activities regarding epidemiology, national 
surveillance, research and technical consultation for pertussis, 
diphtheria, tetanus, polio, measles, mumps, rubella, varicella, 
smallpox, and the vaccines, and toxoids to prevent these diseases, has 
the lead responsibility for immunization safety, and takes an

[[Page 59527]]

active role in the development of immunization policy and vaccine 
recommendations in the United States; (2) collaborates with other CDC 
CIOs in epidemiologic studies and surveillance activities for influenza 
and pneumococcal disease; (3) provides medical and epidemiologic 
expertise and collaborates with other NIP Divisions and CDC CIOs in 
developing strategies to enhance immunization coverage of adults; (4) 
directs national surveillance of diphtheria, pertussis, tetanus, polio, 
Haemophilus influenzae type b (in collaboration with other CDC CIOs), 
measles, mumps, rubella, congenital rubella, varicella, complications 
arising from these diseases, and adverse events following vaccination; 
(5) monitors vaccine safety, and conducts scientific research to 
evaluate the safety of all currently available and new vaccines; (6) 
develops strategies for designated national and international vaccine-
preventable disease control programs and/or disease elimination 
activities; (7) provides epidemic aid in collaboration with other CDC 
CIOs, during outbreaks of vaccine-preventable diseases and consultation 
to State and local health departments and to foreign countries on these 
diseases and their prevention; (8) provides consultation and assistance 
to public health professionals on vaccine-preventable diseases, 
vaccines, and biological products; (9) directs epidemiologic research 
to evaluate the efficacy, safety, and cost effectiveness of vaccines, 
and to study aspects of vaccine-preventable diseases relevant to 
immunization practice; (10) provides scientific and administrative 
support for the Advisory Committee on Immunization Practices in the 
development of vaccine policies and recommendations.
    Delete the titles and functional statements for the Vaccine Safety 
and Development Activity (CJ3-2), Adult Vaccine-Preventable Diseases 
Branch (CJ33), and Child Vaccine-Preventable Diseases Branch (CJ34), 
and insert the following:
    Bacterial Vaccine Preventable Disease Branch (CJ35). (1) Conducts 
epidemiologic research and provides medical expertise on bacterial 
vaccines and vaccine-preventable disease, including diphtheria, 
pertussis, Haemophilus influenzae type b, tetanus, anthrax, and 
pneumococcal disease; (2) provides consultation on the use of vaccines 
and toxoids recommended to prevent these diseases; (3) provides 
consultation and support to State and local health departments in the 
investigation of epidemics and other problems associated with bacterial 
vaccine-preventable diseases, and recommends appropriate control 
measures; (4) conducts national surveillance and prepares and 
distributes surveillance information for diphtheria, pertussis, and 
tetanus; (5) in collaboration with other CDC CIOs, conducts 
surveillance and investigates outbreaks of Haemophilus influenzae type 
b disease and pneumococcal disease; (6) analyzes and prepares 
information and statements for the Advisory Committee on Immunization 
Practices and other advisory committees on diphtheria, pertussis, and 
tetanus, and in collaboration with other CDC CIOs, Haemophilus 
influenzae type b, anthrax, and pneumococcal disease; (7) evaluates the 
effectiveness of activities to prevent bacterial vaccine-preventable 
diseases; (8) conducts epidemiologic studies to determine efficacy and 
safety of vaccines and toxoids recommended to prevent bacterial 
vaccine-preventable diseases; (9) prepares and reviews articles based 
on study findings for publication in professional journals, and makes 
presentations at professional conferences; (10) provides scientific 
support to other CDC CIOs in the development of effective 
communications and techniques to prevent bacterial vaccine-preventable 
diseases; (11) collaborates with the WHO, the Pan American Health 
Organization, as well as other national and international agencies on 
investigating bacterial vaccine-preventable disease outbreaks, 
conducting surveillance and epidemiologic research, and developing 
strategies for the prevention and elimination of bacterial vaccine-
preventable diseases.
    Viral Vaccine Preventable Diseases Branch (CJ36). (1) Conducts 
epidemiologic research and provides medical expertise on viral vaccine-
preventable diseases, including measles, mumps, rubella, polio, 
varicella, influenza, and smallpox; (2) provides consultation on the 
use of vaccines recommended to prevent these diseases; (3) provides 
consultation and support to State and local health departments in the 
investigation of epidemics and other problems associated with viral 
vaccine-preventable diseases, and recommends appropriate control 
measures; (4) conducts national surveillance and prepares and 
distributes surveillance information for measles, mumps, rubella, 
polio, and varicella; (5) in collaboration with other NIP Divisions and 
CDC CIOs, performs surveillance and other emergency response activities 
for viral vaccine-preventable diseases (e.g., surveillance for 
suspected smallpox cases); (6) analyzes and prepares information and 
statements for the Advisory Committee on Immunization Practices and 
other advisory committees on measles, mumps, rubella, polio, and 
varicella, and in collaboration with other CDC CIOs, influenza, 
rotavirus, and smallpox disease; (7) evaluates the effectiveness of 
activities to prevent viral vaccine-preventable diseases; (8) conducts 
epidemiologic studies to determine efficacy and safety of vaccines 
recommended to prevent viral vaccine-preventable diseases; (9) prepares 
and reviews articles based on study findings for publication in 
professional journals, and makes presentations at professional 
conferences; (10) provides scientific support to other CDC CIOs in the 
development of effective communications and techniques to prevent viral 
vaccine-preventable diseases; (11) collaborates with the WHO, the Pan 
American Health Organization, as well as other national and 
international agencies on investigating viral vaccine-preventable 
disease outbreaks, conducting surveillance and epidemiologic research, 
and developing strategies for the prevention and elimination of viral 
vaccine-preventable diseases.
    Immunization Safety Branch (CJ37). (1) Coordinates a national 
surveillance program for monitoring vaccine safety, in collaboration 
with the Food and Drug Administration (FDA); (2) collects, analyzes, 
and evaluates data to determine the safety of designated vaccines; (3) 
prepares and distributes surveillance information pertaining to the 
monitoring of adverse events following immunization; (4) conduct ad-hoc 
studies and investigations pertaining to adverse events following 
immunization; (5) coordinates studies using large linked data bases to 
evaluate the potential causal relationship of vaccination with specific 
health outcomes; (6) collaborates with other CDC CIOs, the FDA, the 
National Institute of Allergy and Infectious Diseases, the Health 
Resources and Services Administration, the Department of Defense, and 
the National Vaccine Program Office in development and execution of a 
coordinated national plan to improve immunization safety; (7) assists 
the National Vaccine Injury Compensation Program in analyzing data from 
cases seeking compensation; (8) provides consultation to State and 
local health departments pertaining to monitoring and reporting of 
adverse events following immunization; (9) prepares articles based on 
findings of studies for publication in professional

[[Page 59528]]

journals and presentation at professional conferences; (10) 
collaborates with partners to develop new and combined vaccines that 
can be integrated into national and international immunization 
programs; (11) participates in trials of new and combined vaccines; 
(12) participates in international as well as domestic vaccine safety 
research activities; and (13) conducts research and evaluates 
alternative approaches for administering vaccines to enhance safety.

    Dated: September 12, 2002.
Julie Louise Gerberding,
Director, Centers for Disease Control and Prevention (CDC).
[FR Doc. 02-24034 Filed 9-20-02; 8:45 am]
BILLING CODE 4160-18-M